To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Immunomodulatory Type II … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Immunomodulatory Type II Natural Killer T Lymphocytes in Health and Disease

Journal article
Authors Sara Rhost
Sai Kiran Sedimbi
N. Kadri
Susanna Cardell
Published in Scandinavian Journal of Immunology
Volume 76
Issue 3
Pages 246-255
ISSN 0300-9475
Publication year 2012
Published at Institute of Biomedicine, Department of Microbiology and Immunology
Pages 246-255
Language en
Keywords invariant nkt cells, immune-response, tumor-immunity, ulcerative-colitis, antitumor-activity, self glycolipids, cross-regulation, virus-infection, cutting edge, recognition, rcelli s, 1993, journal of experimental medicine, v178, p1, llabona p, 1994, journal of experimental medicine, v180, p1171
Subject categories Immunology in the medical area


Natural killer T (NKT) lymphocytes are a beta T cells activated by lipid-based ligands presented on the non-polymorphic CD1d-molecule. Type I NKT cells that carry an invariant Va14 (in the mouse) or Va24 (in humans) T cell receptor a-chain rearrangement have received significant attention for their involvement in a diversity of immune reactions. Their sister population, CD1d-restricted type II NKT cells, has been more difficult to study because of the lack of molecular markers that specify these cells. In the last few years, however, significant progress has been made, demonstrating that type II NKT cells have unique functions in immune responses to tumours and infections, in autoimmunity, obesity and graft-versus-host disease. Type II NKT cells appear more frequent than type I NKT cells in humans and accumulate in certain diseases such as ulcerative colitis, hepatitis and multiple myeloma. Recently, novel type II NKT cell ligands have been identified, and it is becoming clear that the type II NKT cell population may be oligoclonal. Here, we review the recent progress in the study of type II NKT cells, supporting the view that type II NKT cells may be attractive targets for immunotherapy.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?